Clinical Trials Browser

talazoparib × Genitourinary × Clear all

Prostatic Neoplasms

NCT04901702 2026-02-09

Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma

Neoplasms, Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Hepatoblastoma, Neuroectodermal Tumors, Primitive, Peripheral, Rhabdoid Tumor

NCT04734730 2026-01-28

Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer

Phase 2 Recruiting

70 enrolled

Genitourinary

Prostatic Neoplasms

NCT05873192 2025-12-23

Presurgical Phase II Study of Talazoparib in Combination With Enzalutamide in Prostate Cancer

Phase 2 Recruiting

30 enrolled

Genitourinary

Prostatic Neoplasms

NCT06844383 2025-10-29

TALENT

Phase 2 Recruiting

126 enrolled

Genitourinary

Adenocarcinoma, Prostatic Neoplasms

NCT04678362 2025-09-22

TALASUR

Phase 2 Recruiting

50 enrolled

Genitourinary

Carcinoma, Transitional Cell

NCT05650476 2025-06-12

Pre-approval Single-patient Expanded Access for Talazoparib (PF-06944076)

Available

Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

NCT04337970 2025-05-28

Talazoparib and Axitinib for People With Previously Treated Advanced Kidney Cancer

Phase 1/2 Completed

23 enrolled

Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

NCT04332744 2025-05-11

ZZ-First

Phase 2 Completed

54 enrolled

Genitourinary

Prostatic Neoplasms

NCT04846478 2025-04-17

Phase Ia/Ib Talazoparib + Tazemetostat for mCRPC

Phase 1 Active not recruiting

35 enrolled

Genitourinary

Prostatic Neoplasms

NCT04672460 2024-09-25

A Bioequivalence Study Between the Proposed and Current Talazoparib Capsule Formulation and Food Effect Study for the Proposed Talazoparib Capsule Formulation in Participants With Advanced Solid Tumors

Phase 1 Completed

73 enrolled 18 charts

BreastGastrointestinalGenitourinaryGynecologic

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms

NCT03148795 2024-04-05

A Study of Talazoparib in Men With DNA Repair Defects and Metastatic Castration-Resistant Prostate Cancer

Phase 2 Completed

128 enrolled 25 charts

Genitourinary

Prostatic Neoplasms

NCT05425862 2023-12-11

REPAIR

Phase 1 Suspended

48 enrolled

Genitourinary

Metastatic Castration Resistant Prostate Cancer (mCRPC)

NCT03875313 2022-02-17

Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors

Phase 1/2 Terminated

33 enrolled 14 charts

BreastGastrointestinalGenitourinary

Carcinoma, Renal Cell, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT04824937 2021-04-01

Telaglenastat + Talazoparib In Prostate Cancer

Phase 2 Unknown

30 enrolled

Genitourinary

Prostate Cancer Metastatic

NCT01286987 2019-01-10

Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors

Phase 1 Completed

113 enrolled 39 charts

BreastClassical hematologyGastrointestinalGenitourinaryGynecologicSarcomaThoracic

Fanconi Anemia, Complementation Group D1, Carcinoma, Ovarian Epithelial, Breast Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma, Ewing, Small Cell Lung Carcinoma

Clinical Trials

Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC

Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma

Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer

Presurgical Phase II Study of Talazoparib in Combination With Enzalutamide in Prostate Cancer

TALENT

TALASUR

Pre-approval Single-patient Expanded Access for Talazoparib (PF-06944076)

Talazoparib and Axitinib for People With Previously Treated Advanced Kidney Cancer

ZZ-First

Phase Ia/Ib Talazoparib + Tazemetostat for mCRPC

A Bioequivalence Study Between the Proposed and Current Talazoparib Capsule Formulation and Food Effect Study for the Proposed Talazoparib Capsule Formulation in Participants With Advanced Solid Tumors

A Study of Talazoparib in Men With DNA Repair Defects and Metastatic Castration-Resistant Prostate Cancer

REPAIR

Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors

Telaglenastat + Talazoparib In Prostate Cancer

Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors